Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanzi Huangshi Wan
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sanzi Huangshi Wan, also known as Sanzi-huangshi pill (SHP), is a traditional Chinese medicine formulation containing Realgar, Radix pseudostellariae, Semen cuscutae, and Ligustrum lucidum. It is an arsenic-containing medicine being investigated as an adjuvant therapy for lower-risk myelodysplastic syndrome (MDS). Preliminary studies suggest that Sanzi Huangshi Wan may improve erythrocytopenia, thrombocytopenia, and quality of life in patients with lower-risk MDS, potentially by regulating apoptosis and histone acetylation. The formulation is prepared as traditional pills and administered orally.
- Brand names
- Sanzi Huangshi No.1 Pill
- Other names
- Sanzi-huangshi pillSHPSanzi Huangshi No. 1 Pill
Beyond the preview
Go deeper on Sanzi Huangshi Wan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sanzi Huangshi Wan.